Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Compass Therapeutics
ViroMissile, Inc.
Seagen Inc.
SEED Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
MacroGenics
M.D. Anderson Cancer Center
NeoTX Therapeutics Ltd.
West China Hospital
Incyte Corporation
Pfizer
GONGCHU Biotechnology Co., Ltd
Exelixis
Jonsson Comprehensive Cancer Center
University of Virginia
Incyte Corporation
Incyte Corporation
HC Biopharma Inc.
Sotio Biotech Inc.
Carisma Therapeutics Inc
Molecular Templates, Inc.
Xencor, Inc.
Pliant Therapeutics, Inc.
National Cancer Institute (NCI)
BioEclipse Therapeutics
University of Florida
Fate Therapeutics
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
AbbVie
Pfizer
AbbVie
Incyte Corporation
Eli Lilly and Company
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Inovio Pharmaceuticals
AbbVie
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
City of Hope Medical Center
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)